You are here

  • Home
  • Archive
  • Volume 77, Issue 5
  • Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study

Article metrics

Article menu
Download PDFPDF
Clinical and epidemiological research
Extended report
Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study

 

Online download statistics by month:

Online download statistics by month: February 2018 to March 2024

AbstractFullPdf
Feb 2018154014075
Mar 20182306182111
Apr 20181416201107
May 201879812490
Jun 20183485540
Jul 20181482822
Aug 20181994223
Sep 20181652719
Oct 2018135229
Nov 20181532713
Dec 201892711
Jan 20191232412
Feb 20192103619
Mar 20192612819
Apr 2019841412
May 2019951612
Jun 2019871513
Jul 2019107197
Aug 2019129115
Sep 2019128206
Oct 2019134104
Nov 201958123
Dec 20197666
Jan 20208693
Feb 2020103156
Mar 20209675
Apr 20207366
May 202095912
Jun 20209063
Jul 20201141310
Aug 20207394
Sep 20209986
Oct 2020102136
Nov 202099176
Dec 2020132248
Jan 202194196
Feb 20214644
Mar 20217773
Apr 20214258
May 202137114
Jun 202112116
Jul 2021955
Aug 2021433
Sep 202116132
Oct 20215074
Nov 20217852
Dec 2021145102
Jan 20227031
Feb 20227023
Mar 20226182
Apr 202219563
May 20229011
Jun 20229393
Jul 20227096
Aug 202213255
Sep 202210295
Oct 202210230
Nov 20226871
Dec 20227111
Jan 2023116125
Feb 202310540
Mar 20233832
Apr 20237423
May 20235062
Jun 20233622
Jul 20238581
Aug 20238656
Sep 20237020
Oct 20235431
Nov 20236021
Dec 2023152101
Jan 20247195
Feb 20247652
Mar 20247795
Total128381447829